Up a level |
Kityo, Cissy, Thompson, Jennifer, Nankya, Immaculate, Hoppe, Anne, Ndashimye, Emmanuel, Warambwa, Colin, Mambule, Ivan, van Oosterhout, Joep J, Wools-Kaloustian, Kara, Bertagnolio, Silvia et al (show 4 more authors)
(2017)
HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 75 (2).
E45-E54.
Hakim, James G, Thompson, Jennifer, Kityo, Cissy, Hoppe, Anne, Kambugu, Andrew, van Oosterhout, Joep J, Lugemwa, Abbas, Siika, Abraham, Mwebaze, Raymond, Mweemba, Aggrey et al (show 7 more authors)
(2017)
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
The Lancet. Infectious diseases, 18 (1).
pp. 47-57.
Paton, Nicholas I, Kityo, Cissy, Thompson, Jennifer, Nankya, Immaculate, Bagenda, Leonard, Hoppe, Anne, Hakim, James, Kambugu, Andrew, van Oosterhout, Joep J, Kiconco, Mary et al (show 5 more authors)
(2017)
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
The lancet. HIV, 4 (8).
e341-e348.